• Home
  • Study Details
By physician referral or invitation only

Testing CC-486 Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, ransformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

To determine if patients that are 75 years of age or older who were recently diagnosed with DLBCL be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12 weeks) without significantly more side effects than patients taking the standard drug therapy alone; have longer, shorter, or the same amount of time without the disease getting worse (progression) than patients taking the standard drug therapy alone; live longer, live the same amount of time, or live a shorter amount of time than patients taking the standard drug therapy alone. This study is being done to find out if this approach is better or worse than the usual approach for the DLBCL. The usual approach is defined as care most people get for DLBCL.

Age & Gender

  • 75 years ~ 99 years
  • Male, Female

Contact the Team


Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Anne Beaven

Study Type

Clinical or Medical

Study Topics

Cancer (Lymphoma)

IRB Number




Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research